Trial reportFrontiers in aging2026
CaroRite™ for improving skin health and the visible signs of aging - a randomised, double-blind, placebo-controlled trial.
Trial report in Frontiers in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06878001 (CaroRite™ for Improving Skin Health and the Visible Signs of Ageing, a Placebo Controlled, Double Blind, Randomised Clinical Trial), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CaroRite™ for Improving Skin Health and the Visible Signs of Ageing, a Placebo Controlled, Double Blind, Randomised Clinical Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is an increasing need to identify novel ingredients that can be safely utilized to enhance skin function and mitigate skin aging. Carotenoid supplementation shows promise in improving skin health and reducing signs of aging, owing to its antioxidant and anti-inflammatory properties. Aim: This randomised, double-blind, placebo-controlled study aimed to investigate the efficacy of a carotenoid supplement, CaroRite™, on skin health and the visible signs of aging in healthy females. Methods: Eighty female participants aged 40-55 years were recruited and randomised to receive either CaroRite™ (containing 28-30 mg mixed carotenoids) or a placebo. Participants were instructed to take one capsule daily for 12 weeks. Outcome measures included visible signs of aging (wrinkles, skin elasticity, hydration, sebum, pigmentation, pore size, and temperature), transepidermal water loss (TEWL), dermal thickness, skin carotenoid levels, dietary carotenoid intake, and safety. Results: No significant between-group differences were observed for visible signs of aging parameters (p > 0.05). At week 12, significant between-group differences from baseline were observed for TEWL (CaroRite™ -4.58 ± 9.43 vs. placebo 0.34 ± 6.73; p = 0.011) and dermal thickness (CaroRite™ 139.50 ± 220.21 μm vs. placebo 43.90 ± 225.97 μm; p = 0.036). Skin carotenoid levels increased by 48.1% in the active group (CaroRite™ +167.09 ± 117.23 vs. placebo 9.42 ± 47.16; p < 0.001), despite no significant differences in dietary carotenoid intake between groups. Conclusion: Daily oral supplementation with CaroRite™ did not reduce the visible signs of ageing after 12 weeks, however notable improvements in skin carotenoid status, TEWL and dermal thickness was found. CaroRite™ demonstrated good bioavailability and was well tolerated. Overall, these findings support the use of CaroRite™ as part of a comprehensive approach to potentially improving skin health, particularly for enhancing skin carotenoid status and supporting underlying structural and barrier function. Clinical Trial Registration: ClinicalTrials.gov, Identifier NCT06878001.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.